Curocell큐로셀

Curocell remains loss-making with no reported revenue, and its share price is down about 42% over the past year.

Curocell, a Korean biotech listed on KOSDAQ since November 2023, reported zero revenue and large operating losses in both its latest trailing twelve months to H1 2026 and in 2025. The stock closed at ₩23,150 on 13 October 2026, a market value of about ₩353B, near its 52-week low of ₩20,650 and well below its high of ₩66,000. The data does not include a company profile or recent news.

What stands out

• Trailing twelve-month operating loss is about -₩35.4B and net loss about -₩54.1B, with no revenue reported.
• Free cash flow is about -₩30.3B, and borrowings of ₩34.4B exceed cash of ₩17.1B.
• Liabilities are 127% of equity, and the price-to-book ratio is 4.9x, while P/E and EV/EBITDA cannot be calculated because earnings are negative.
• Recent filings are mostly shareholding and holding reports, plus a half-year report for June 2026 filed 14 August 2026 and a major management matter in June 2026.
• The company profile and news headlines are not in the data, so the reason for the management matter and the business plan cannot be confirmed here.

What to watch

• The contents of the June 2026 management matter and any follow-up disclosures, which the data does not describe.
• Cash runway: cash of ₩17.1B against negative free cash flow and ₩34.4B in borrowings.
• Future filings on revenue or product milestones, since no revenue has been reported in the data provided.